Overview
- Teijin Limited and Hyderabad-based UR Advanced Therapeutics (BioVaram) signed a business-alliance agreement to collaborate on regenerative medicine and implantable devices across both markets.
- The companies will explore regulatory approval and potential commercialization in India of Teijin Medical Technologies’ SYNFOLIUM cardiovascular repair patch.
- The partners will assess opportunities to expand the use in India of Japan Tissue Engineering (J‑TEC) regenerative medicine products from the Teijin Group.
- In Japan, the alliance targets development and commercialization of BioVaram technologies, including exosome-based diagnostics and therapeutics, extracellular matrix mimics, and Type I atelocollagen.
- Near-term work focuses on business feasibility, regulatory pathways, technical integration, and potential joint product development and manufacturing, including cell and gene therapy.